ClinicalTrials.gg
RecruitingNCT07398339DVDMSUpdated Nov 18, 2026

Cosiporfin Sodium for Injection Photodynamic Therapy

A Phase 2 interventional study of Cosiporfin Sodium for injection, DVDMS and Gemcitabine Hydrochloride for Injection in Biliary Tract Cancers (BTC), sponsored by Shanghai Guangsheng Biopharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Guangsheng Biopharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 177 studies in Biliary Tract Neoplasms with a site in China — 94 open to participants now, 112 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
128th of 158
30 · median 61
Started
2026
with 33 others
Phase 2
95 of 177
53 open now
Primary completion
2027-03
later than 46 of 111 live
Registered
141st of 177
by date

Among the 177 studies in Biliary Tract Neoplasms with a site in China, this one is the 128th largest by planned enrollment of the 158 interventional ones that give a count, is one of 34 that started in 2026, is one of 95 in phase 2, reaches primary completion later than 46 of the 111 other live ones, and was the 141st registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

94 of the 177 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

Study Design: Multicenter, open-label, Single Group Study Population: Patients with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery.

Primary Research Objective: To preliminarily evaluate the efficacy of photodynamic therapy (PDT) with sodium protoporphyrin combined with gemcitabine and cisplatin (GC regimen) chemotherapy in patients with advanced extrahepatic cholangiocarcinoma complicated by biliary obstruction.

Secondary Study Objective: To preliminarily evaluate the safety and tolerability of photodynamic therapy (PDT) with heme porphyrin sodium combined with gemcitabine and cisplatin (GC regimen) chemotherapy in patients with advanced extrahepatic cholangiocarcinoma with biliary obstruction.

Primary endpoint: 6-month overall survival rate (6m-OS rate)

03

Conditions studied

  • Biliary Tract Cancers (BTC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following inclusion criteria to be enrolled in this study:

    1. All subjects or their legal representatives must voluntarily sign an ethics committee-approved form in writing prior to initiating any screening procedures;
    2. Age ≥ 18 years, no gender restrictions;
    3. Patients with or cytologically confirmed, locally advanced or recurrent extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery;
    4. No prior systemic therapy during the recurrent or metastatic stage;
    5. Presence of obstructive lesions in the extrahepatic bile ducts, with at least one outside the bile ducts according to the (RECIST) 1.1;
    6. Subjects with an performance status score of 0 or 1 (see Appendix 3 for details);
    7. Subjects with an expected survival of ≥3 months;
    8. Subjects with adequate organ and bone marrow function meeting the following laboratory criteria:

      • Bone marrow function: (ANC) ≥1.5 × 10⁹/L (1500/mm³) ; ≥100 × 10⁹/L (1 × 10⁵/mm³); ≥9.0 g/dL (no treatment for bone marrow suppression, such as GCS-F, EPO, or blood transfusion, within 14 days prior to screening laboratory tests);
      • Renal Function: (Ccr) ≥50 mL/min (calculated using the Cockcroft-Gault formula; see Appendix 4);
      • Coagulation Function: (INR) ≤1.5 × ; Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN;
      • Echocardiogram: (LVEF) ≥50%;
      • 12-lead : Fridericia- interval (QTcF) \<470 msec (Appendix 4);
    9. Recovered from all prior treatments with toxicities resolved to Grade 1 or below;
    10. Female subjects of and all male subjects must agree to use highly effective during the trial and for 6 months after the last dose of sodium porphyrin. contraceptive gel, contraceptive film, intrauterine device, oral or injectable contraceptives, subcutaneous implant, etc.), and women of childbearing potential must have a negative pregnancy test result within ≤7 days prior to study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following criteria are ineligible for enrollment:

    1. Patients with ampullary cancer;
    2. Known to sodium porphyrin or other photosensitizing agents;
    3. Diffuse liver or liver tumor burden exceeding 50% of liver volume;
    4. Known or suspected , , or spinal cord compression (including asymptomatic cases and those adequately treated);
    5. Subjects who participated in any other drug clinical trial or other interventional clinical trial within 4 weeks prior to study drug administration, except for subjects participating in observational (non-interventional) clinical studies or those already in the follow-up period of an interventional study;
    6. Previous exposure to photosensitizers or photodynamic therapy;
    7. Patients with unremovable stents in the extrahepatic bile ducts;
    8. Patients with prior history of immunotherapy (including but not limited to various monoclonal antibodies, anti-PD-L1 monoclonal antibodies, anti-CTLA-4 monoclonal antibodies, etc.), gemcitabine, or cisplatin treatment;
    9. Subjects who underwent major surgery within 4 weeks prior to study drug administration;
    10. Subjects who used Chinese herbal medicines with immunomodulatory or antitumor effects within 14 days prior to study drug administration;
    11. Subjects with advanced cholangiocarcinoma in a cachectic state or who are not expected to tolerate photodynamic therapy;
    12. Patients with Bismuth Type IV hilar cholangiocarcinoma;
    13. Individuals unsuitable for ERCP or endoscopic procedures;
    14. Subjects requiring concomitant antitumor therapy during study drug treatment, including chemotherapy regimens other than GC, radiotherapy, immunotherapy, or biologic agents;
    15. Any other diagnosed within 5 years prior to the first study drug administration, except for any type of carcinoma in situ, micro- or low-risk papillary thyroid carcinoma, and cured basal cell carcinoma or squamous cell carcinoma of the skin;
    16. History of allogeneic organ transplantation, or known history of or allogeneic hematopoietic stem cell transplantation;
    17. Presence of (malignant/cancerous, or moderate to large volume) pleural effusion, ascites, or pericardial effusion within 4 weeks prior to the first dose of porphyrin sodium; however, subjects with only small amounts of effusion (untreated) identified by imaging may be eligible;
    18. Presence of acute inflammation (especially necrotizing inflammation) or clinically significant active infection;
    19. virus (HCV) RNA positive, active syphilis, or positive results for any one or more of the following: (HIV) antibody test, or active (defined as HBV DNA ≥ 2000 IU/mL or HBV DNA ≥ 10⁴ copies);
    20. Clinically significant cardiovascular disease or conditions, including but not limited to:

      1. Myocardial infarction within 6 months prior to first dosing;
      2. Uncontrolled angina pectoris within 3 months prior to first dosing;
      3. History or current presence of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes) or other ≥ Grade 2 persistent arrhythmias (per v5.0);
      4. History or current presence of congestive heart failure [ (NYHA) Class III or IV (Appendix 5)];
      5. Complete left bundle branch block or complete right bundle branch block with left anterior fascicular block (double bundle branch block);
      6. Long syndrome or confirmed family history of long QT syndrome; known concomitant use of QT-prolonging medications;
      7. Bradycardia, defined as a screening showing a heart rate \< 45 beats per minute;
      8. Hypotension, defined as a screening systolic blood pressure ≤86 millimeters of mercury (mmHg);
      9. Uncontrolled hypertension, where the subject receives standard antihypertensive therapy but has a screening systolic blood pressure > 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg;
    21. Cerebrovascular events (including hemorrhagic, ischemic, ), cranial surgery, or unexplained loss of consciousness within 6 months prior to the first dose;
    22. Severe pre-existing conditions such as interstitial lung disease, severe dyspnea occurring at rest or requiring supplemental oxygen, inability to lie flat due to acute asthma exacerbation or respiratory failure, active or chronic liver disease, severe hepatic impairment [ Class C], hemorrhagic disorders secondary to hepatic insufficiency, hepatic encephalopathy, etc.; epilepsy or conditions likely to induce seizures; diseases requiring systemic therapy [including immunosuppressants such as anti-TNF monoclonal antibodies, (nasal inhalation or topical application permitted)]; history of adrenal insufficiency;
    23. Thromboembolic disease within 6 months prior to first dose;
    24. Uncontrolled psychiatric illness/social circumstances expected to limit compliance with study requirements or impair the subject's ability to provide written ;
    25. Known history of psychiatric drug abuse or substance abuse;
    26. Pregnant or lactating women;
    27. Receipt of a within 4 weeks prior to the first dose;
    28. Other reasons deemed by the investigator to make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cosiporfin Sodium for injection Combination Therapy Group

    Cosiporfin Sodium for injection Photodynamic Therapy Combined with Gemcitabine and Cisplatin Chemotherapy

    Drug: Cosiporfin Sodium for injection, DVDMS · Drug: Gemcitabine Hydrochloride for Injection · Drug: Cisplatin for injection

Interventions

  • DrugCosiporfin Sodium for injection, DVDMS

    Dosage: 0.2 mg/kg Storage: 2-8°C. Protect from light. Specifications: 10mg per bottle

  • DrugGemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Specifications: 1.0g/vial, 5 vials/box Storage: Store at room temperature (15-30°C) Dosage: 1000mg/m²

  • DrugCisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Specifications: 20mg/vial, 8 vials/box Storage: Store in a light-protected, tightly closed container (10-30°C) Dosage: 25mg/m²

06

What researchers measure

Primary outcomes

  1. 6-month overall survival rate (6m-OS rate)

    Time frame: Month 6

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Month 12&Month 24

  2. Disease Control Rate (DCR)

    Time frame: Month 12&Month 24

  3. Progression-Free Survival (PFS)

    Time frame: Month 12&Month 24

  4. Duration of Response (DoR)

    Time frame: Month 12&Month 24

  5. Overall Survival (OS)

    Time frame: Month 12&Month 24

  6. 12/24-Month Survival Rate

    Time frame: Month 12&Month 24

  7. Time to First Chemotherapy

    Time frame: Month 12&Month 24

  8. Time to Jaundice Recurrence/Recurrence Rate

    Time frame: Month 12&Month 24

07

Study locations

1 of 1 sites recruiting
  • No. 266, Trumpet Vine Road
    Shanghai, Pudong New Area 200120, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 8 months after the start.

Of 132 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's planned 8 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jul 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 9, 2026
StartActual
Jul 16, 2026was Mar 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 31, 2026→Jul 16, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Mar 31, 2026→Jul 16, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07398339
Lead sponsor
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jul 16, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

yu xin Xue
Contact
xinyu.xue@shgsmed.com
13151915398

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion